HomeCDXC • NASDAQ
Chromadex Corp
$3.48
After Hours:
$3.49
(0.29%)+0.0100
Closed: Mar 28, 6:50:35 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$3.67
Day range
$3.17 - $3.77
Year range
$1.25 - $4.06
Market cap
262.08M USD
Avg Volume
395.04K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
21.20M0.95%
Operating expense
13.10M-2.64%
Net income
114.00K108.04%
Net profit margin
0.54108.00%
Earnings per share
0.00100.00%
EBITDA
48.00K104.07%
Effective tax rate
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
27.17M33.93%
Total assets
54.96M1.68%
Total liabilities
26.51M4.42%
Total equity
28.46M
Shares outstanding
75.48M
Price to book
9.66
Return on assets
-0.77%
Return on capital
-1.34%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
114.00K108.04%
Cash from operations
649.00K297.87%
Cash from investing
-21.00K87.79%
Cash from financing
-76.00K-100.99%
Net change in cash
552.00K-92.31%
Free cash flow
823.00K101.96%
About
ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ. In 2011, ChromaDex licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound under the brand name pTeroPure. ChromaDex no longer sells pTeroPure. Wikipedia
Founded
1999
Employees
106
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu